search
Back to results

Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia? (PROFAS)

Primary Purpose

BRCA1/2 Mutation, Bilateral Prophylactic Mastectomy, Seroma

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Fascia pectoralis preservation
Sponsored by
Erasmus Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for BRCA1/2 Mutation

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female patient
  • Scheduled for a bilateral prophylactic mastectomy in the Erasmus MC Academic Breast Cancer Centre in Rotterdam
  • Ability to give written consent
  • Adequate understanding of Dutch language

Exclusion Criteria:

  • History of diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS)
  • Other malignancies

Sites / Locations

  • Erasmus Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Right: removal of fascia pectoralis, left: preservation of fascia pectoralis

Left: removal of fascia pectoralis, right: preservation of fascia pectoralis

Arm Description

Outcomes

Primary Outcome Measures

Drainproduction in milliliters
The total drainage volume of the left and right breast in milliliters
Time to drain removal in days
Number of days until drain removed

Secondary Outcome Measures

Seroma (yes/no)
Occurrence of seroma
Needle aspirations (number)
Number of needle aspirations
Postoperative pain (score 1-10)
Postoperative pain measured with Visual Analogue Scale
Postoperative bleeding (yes/no)
Occurrence of postoperative bleeding
Wound related issues (yes/no)
Wound related issues such as hematoma or infection
Hospitalization duration (in days)
Duration of hospitalization, including readmissions

Full Information

First Posted
May 17, 2022
Last Updated
January 10, 2023
Sponsor
Erasmus Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05391763
Brief Title
Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?
Acronym
PROFAS
Official Title
Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?: Protocol of a Dutch Double Blinded, Prospective, Randomized Controlled Pilot Study With a Within-subject Design
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Many surgical guidelines promote the removal of the pectoral fascia in mastectomies for invasive breast cancer, but there is no evidence to support this statement in (bilateral) prophylactic mastectomies. Reported wound-related local complications following mastectomy include seroma, flap necrosis, infection, hematoma, and nerve injury. Seroma causes discomfort and may delay the reconstructive procedures. Whether the removal or preservation of the pectoral fascia influences seroma formation following mastectomy remains unclear to our knowledge.
Detailed Description
The primary objective of this pilot study is to investigate the impact of removal versus preservation of the pectoral fascia on drain policy and needle aspirations in women who undergo a bilateral prophylactic mastectomy. The secondary objective is to investigate the impact of removal versus preservation of the pectoral fascia on postoperative (surgical) complications. The study design includes a double-blinded, prospective, randomized controlled pilot study with a within-subject design. All patients will undergo a bilateral prophylactic mastectomy and randomization will occur within the patient. Preservation of the PF will be performed in one breast (intervention), while removal of the PF will be performed in the contralateral breast of the same patient (control). Consequently, the operation involves a total bilateral prophylactic mastectomy, with unilateral preservation of the PF The follow-up time of each patient will be 6 weeks. The patients' files will be viewed after the removal of the drain for additional recorded variables.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
BRCA1/2 Mutation, Bilateral Prophylactic Mastectomy, Seroma, Pectoral Fascia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Masking Description
The patient and the observer for drain volume are both blinded for their assigned breast randomization. The surgeon(s) and coordinating researcher will not be blinded, and are therefore not allowed to measure the drain production.
Allocation
Randomized
Enrollment
21 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Right: removal of fascia pectoralis, left: preservation of fascia pectoralis
Arm Type
Other
Arm Title
Left: removal of fascia pectoralis, right: preservation of fascia pectoralis
Arm Type
Other
Intervention Type
Procedure
Intervention Name(s)
Fascia pectoralis preservation
Intervention Description
A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
Primary Outcome Measure Information:
Title
Drainproduction in milliliters
Description
The total drainage volume of the left and right breast in milliliters
Time Frame
Until drain removal, maximum 1 week
Title
Time to drain removal in days
Description
Number of days until drain removed
Time Frame
Until drain removal, maximum 1 week
Secondary Outcome Measure Information:
Title
Seroma (yes/no)
Description
Occurrence of seroma
Time Frame
Up to 6 weeks
Title
Needle aspirations (number)
Description
Number of needle aspirations
Time Frame
Up to 6 weeks
Title
Postoperative pain (score 1-10)
Description
Postoperative pain measured with Visual Analogue Scale
Time Frame
Up to 6 weeks
Title
Postoperative bleeding (yes/no)
Description
Occurrence of postoperative bleeding
Time Frame
Up to 6 weeks
Title
Wound related issues (yes/no)
Description
Wound related issues such as hematoma or infection
Time Frame
Up to 6 weeks
Title
Hospitalization duration (in days)
Description
Duration of hospitalization, including readmissions
Time Frame
Up to 6 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patient Scheduled for a bilateral prophylactic mastectomy in the Erasmus MC Academic Breast Cancer Centre in Rotterdam Ability to give written consent Adequate understanding of Dutch language Exclusion Criteria: History of diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS) Other malignancies
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marloes Clarijs, MD
Phone
+31 6 22035529
Email
m.clarijs@erasmusmc.nl
Facility Information:
Facility Name
Erasmus Medical Center
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Linetta Koppert, MD, PhD, MHS
Phone
+31107040151
Email
l.koppert@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
Linetta Koppert, MD, PhD, MHS
First Name & Middle Initial & Last Name & Degree
Dalibor Vasilic, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?

We'll reach out to this number within 24 hrs